CNBG-VIROGIN BIOTECH(SHANGHAI)CO.,LTD. ("CNBG") is a Sino-foreign joint venture jointly funded by China Biotechnology Co., Ltd. and Shanghai Fu Nuojian Biotechnology Co., Ltd. The company was established in 2019. Established in May 2005, located in Nanxiang Precision Medicine Industrial Park, Jiading District, Shanghai. After the establishment of the company, the company will give full play to the advantages of China Biotech and Fonova in the fields of R&D, clinical, production, sales, etc. To achieve complementary advantages, collaborative innovation, use viral vectors as a platform, and introduce a new generation of oncolytic viruses, mRNA vaccines, and vector vaccines. And a series of products such as personalized precision diagnosis and treatment. On September 25, 2021, CNBG-Virogin mRNA vaccine industrialization base officially started. CNBG-Virogin mRNA vaccine industrialization base is aimed at the mutation of new coronavirus The vaccine research and development and industrialization project of the strain, with a total construction area of 32513.86 square meters and a production workshop of more than 16,000 square meters. After completion and commissioning, it will become a domestically leading mRNA vaccine production workshop in terms of design capacity and technology, which fully meets the needs of biomedical automation and informatization. , Intelligent and international requirements, to create a low-carbon, energy-saving, and environmentally friendly modern intelligent mRNA vaccine industrialization base.
mRNA, also known as messenger RNA, is the information transmitter in the process of gene expression: DNA carrying human genetic information is transcribed in the nucleus to produce mRNA, and then mRNA is translated in the cytoplasm to produce proteins that perform various physiological functions. The LPP delivery platform delivers mRNA synthesized in vitro to specific cells in the human body, and then the mRNA is translated in the cytoplasm into proteins or polypeptides required for immunotherapy, so as to achieve the effect of treating or preventing diseases. Unlike DNA, mRNA does not need to be expressed in the nucleus, thus reducing technical difficulties and the risk of altering the cell genome.
Oncovirus is a type of tumor-killing virus with replication ability. The first report of oncolytic virus appeared in the world because it was discovered that a patient with cervical cancer was infected with rabies virus and the tumor subsided.
Caring for life and health
Love and responsibility
To become an innovative biomedical company that leads the development of the domestic industry, has international competitiveness, and is respected by the society.
On May 18, 2019, Sino Biotech and Biotech Canada jointly established CNBG-VIROGIN BIOTECH(SHANGHAI)CO.,LTD. The joint venture company achieves complementary advantages and collaborative innovation. It uses viral vectors as a platform to develop and introduce a new generation of oncolytic viruses, vector vaccines and other products, becoming a leader in the field of tumor immunotherapy in China and bringing new dawn to the majority of tumor patients.
On September 17, 2020, the world's first new oncolytic virus VG161 carrying four synergistic immune regulatory factors successfully obtained CDE's drug clinical trial approval, agreeing to VG161 to carry out clinical trials for the treatment of advanced malignant solid tumors with injectable lesions.
On May 13, 2021, the construction of the mRNA vaccine platform was officially launched. Forward-looking layout of mRNA vaccine platform, establishment of large-throughput mRNA structure screening technology with independent intellectual property rights, etc., to create a unique global mRNA vaccine research and development platform.
